These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33378180)

  • 1. Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.
    Dietrich JD; Longenecker KL; Wilson NS; Goess C; Panchal SC; Swann SL; Petros AM; Hobson AD; Ihle D; Song D; Richardson P; Comess KM; Cox PB; Dombrowski A; Sarris K; Donnelly-Roberts DL; Duignan DB; Gomtsyan A; Jung P; Krueger AC; Mathieu S; McClure A; Stoll VS; Wetter J; Mankovich JA; Hajduk PJ; Vasudevan A; Stoffel RH; Sun C
    J Med Chem; 2021 Jan; 64(1):417-429. PubMed ID: 33378180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFalpha as therapeutic target: new drugs, more applications.
    Reimold AM
    Curr Drug Targets Inflamm Allergy; 2002 Dec; 1(4):377-92. PubMed ID: 14561184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.
    Lim H; Lee SH; Lee HT; Lee JU; Son JY; Shin W; Heo YS
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFα through combined in silico/in vitro/in vivo screening.
    Mouhsine H; Guillemain H; Moreau G; Fourati N; Zerrouki C; Baron B; Desallais L; Gizzi P; Ben Nasr N; Perrier J; Ratsimandresy R; Spadoni JL; Do H; England P; Montes M; Zagury JF
    Sci Rep; 2017 Jun; 7(1):3424. PubMed ID: 28611375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches.
    Xiao HY; Li N; Duan JJ; Jiang B; Lu Z; Ngu K; Tino J; Kopcho LM; Lu H; Chen J; Tebben AJ; Sheriff S; Chang CY; Yanchunas J; Calambur D; Gao M; Shuster DJ; Susulic V; Xie JH; Guarino VR; Wu DR; Gregor KR; Goldstine CB; Hynes J; Macor JE; Salter-Cid L; Burke JR; Shaw PJ; Dhar TGM
    J Med Chem; 2020 Dec; 63(23):15050-15071. PubMed ID: 33261314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases.
    Bystrom J; Clanchy FI; Taher TE; Mangat P; Jawad AS; Williams RO; Mageed RA
    Cytokine; 2018 Jan; 101():4-13. PubMed ID: 27639923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposing novel TNFα direct inhibitor Scaffolds using fragment-docking based e-pharmacophore modeling and binary QSAR-based virtual screening protocols pipeline.
    Zaka M; Abbasi BH; Durdagi S
    J Mol Graph Model; 2018 Oct; 85():111-121. PubMed ID: 30149308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modifying TNFalpha for therapeutic use: a perspective on the TNF receptor system.
    Hasegawa A; Takasaki W; Greene MI; Murali R
    Mini Rev Med Chem; 2001 May; 1(1):5-16. PubMed ID: 12369987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor -kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking.
    Nii T; Kuzuya K; Kabata D; Matsui T; Murata A; Ohya T; Matsuoka H; Shimizu T; Oguro E; Okita Y; Udagawa C; Yoshimura M; Kudo-Tanaka E; Teshigawara S; Harada Y; Yoshida Y; Isoda K; Tsuji SI; Ohshima S; Hashimoto J; Shintani A; Takehana Y; Tohma S; Saeki Y
    J Autoimmun; 2019 Mar; 98():95-102. PubMed ID: 30591403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis.
    Manfredi AA; Baldini M; Camera M; Baldissera E; Brambilla M; Peretti G; Maseri A; Rovere-Querini P; Tremoli E; Sabbadini MG; Maugeri N
    Ann Rheum Dis; 2016 Aug; 75(8):1511-20. PubMed ID: 26819099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
    Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G
    Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis.
    Brennan FM; Hayes AL; Ciesielski CJ; Green P; Foxwell BM; Feldmann M
    Arthritis Rheum; 2002 Jan; 46(1):31-41. PubMed ID: 11822409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases.
    Lee JU; Shin W; Son JY; Yoo KY; Heo YS
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28124979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of aryl hydrocarbon receptor ligands derived from natural products in rheumatoid arthritis.
    Hui W; Dai Y
    Basic Clin Pharmacol Toxicol; 2020 Jun; 126(6):469-474. PubMed ID: 31811747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate.
    Varani K; Massara A; Vincenzi F; Tosi A; Padovan M; Trotta F; Borea PA
    Arthritis Rheum; 2009 Oct; 60(10):2880-91. PubMed ID: 19790066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab.
    Ono M; Horita S; Sato Y; Nomura Y; Iwata S; Nomura N
    Protein Sci; 2018 Jun; 27(6):1038-1046. PubMed ID: 29575262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin.
    Xu H; Liu P; Liang L; Danesh FR; Yang X; Ye Y; Zhan Z; Yu X; Peng H; Sun L
    Arthritis Rheum; 2006 Nov; 54(11):3441-51. PubMed ID: 17075836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines and anti-cytokine biologicals in autoimmunity: present and future.
    Andreakos ET; Foxwell BM; Brennan FM; Maini RN; Feldmann M
    Cytokine Growth Factor Rev; 2002; 13(4-5):299-313. PubMed ID: 12220545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.